CRVS Corvus Pharmaceuticals Inc Earnings per share for the last twelve months

Symbol and logo of brand Corvus Pharmaceuticals (CRVS)

The potential of Corvus Pharmaceuticals (CRVS) is based on the implementation of targeted immunotherapies for lymphoma treatment. On GURU.Markets, the 12-month net income per share trend demonstrates the model's adaptability, where -0.70 represents the current metric. However, business sustainability depends on test results and competition, while the start of final Phase 3 trials is still being established.

CRVS Corvus Corp Earnings per one share for the last 12 months (07/04/2022 - 11/17/2026)

Analytical breakdowns and data insights for company Corvus Corp (CRVS)

- share price and expert price forecast:
Fundamental valuation:CRVS - Corvus Corp
Mass-produced product of Corvus Pharmaceuticals Inc

This indicator reflects the annual net income per share, allowing investors to filter out market noise and assess the actual return on equity. By analyzing the 12-month rolling earnings per share, an investor can see the impact of geopolitical barriers and logistics disruptions on drug development costs, which inevitably hinders the profit growth of Corvus Pharmaceuticals (CRVS) due to the complexity of international trials.